ArticleNeurosurgical review2024
"Navigating moyamoya: bridging gaps in neurocognitive outcomes through STA-ACA bypass".
Article in Neurosurgical review, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
With its bimodal age distribution, higher prevalence in Far East Asian populations, and significant risk of ischemic stroke, Moyamoya disease (MMD) poses a distinctive clinical challenge. In a recently published study by Sho Tsunoda et al., the neurocognitive results of patients with MMD undergoing revascularization surgery were assessed, highlighting the potential advantages of superficial temporal artery to anterior cerebral artery (STA-ACA) direct bypass in ameliorating neuropsychological impairment. Despite its propitious findings, the study's limitations-including a small sample size, single-center design, and lack of long-term follow-up-underscore the need for further research. Future multicenter, prospective trials with larger patient cohorts and comprehensive neurocognitive assessments are essential to validate these results and enhance the generalizability of the findings. This letter emphasizes the importance of robust study designs in advancing our understanding of MMD treatment and ensuring better patient outcomes.
Indexed as
Identifiers
39367116What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.